EMA Authorised: Palsonify (paltusotine hydrochloride) — Crinetics Pharmaceuticals Europe GmbH

View source ↗

Summary

Palsonify (paltusotine hydrochloride) has been authorised in Europe for acromegaly by Crinetics Pharmaceuticals Europe GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• PALSONIFY (PALTUSOTINE)

Snippet

Status: Authorised. Therapeutic area: Acromegaly. MAH: Crinetics Pharmaceuticals Europe GmbH. Decision date: 29/07/2026. Orphan medicine